摘要
目的:探讨程序性死亡分子1(PD-1)/PD-1配体(PD-L1)抑制剂卡瑞利珠联合卡培他滨和奥沙利铂在治疗结直肠癌晚期病人方面的效果。方法:挑选我院实施相应治疗的结直肠癌(晚期)107例为研究对象,按照随机数表法将其分成2组。对照组54例患者实施卡培他滨结合奥沙利铂治疗;观察组53例患者则另外加用卡瑞利珠单抗予以相应的治疗。比较两组患者治疗效果和不良反应,治疗前后血清的血管内皮生长因子(VEGF)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、甲胎蛋白(AFP)水平。结果:观察组患者治疗结束后总有效率(RR)以及疾病的具体控制率(DCR)[分别是(45.28)%、(71.70)%]高于对照组病人[分别是(25.93)%、(38.89)%](χ^(2)=4.38,4.25,P=0.036,0.039)。治疗后观察组血清里面的CA19-9、VEGF、AFP、CEA具体的浓度[分别是(280.21±11.67)ng·L^(-1)、(51.52±8.22)U·mL^(-1)、(7.49±0.98)ng·mL^(-1)、(21.37±3.19)ng·mL^(-1)]低于对照组[分别是(310.37±12.83)ng·L^(-1)、(60.28±7.83)U·mL^(-1)、(11.33±1.72)ng·mL^(-1)、(28.51±4.28)ng·mL^(-1)](t=12.66,5.62,14.12,9.74,P<0.05)。结论:奥沙利铂和卡培他滨联合卡瑞利珠单抗治疗结直肠癌(晚期)患者疗效方面的较好,可在临床上推广使用。
Objective:To investigate the efficacy of programmed cell death molecule 1(PD-1)/PD-1 ligand(PD-L1)inhibitor Carelizumab combined with capecitabine and oxaliplatin in the treatment of advanced colorectal cancer.Methods:A total of 107 patients with advanced colorectal cancer recieving corresponding treatment regimens in our hospital were enrolled in this trial and randomized into two groups.The 54 patients in the control group were treated with capecitabine combined with oxaliplatin and 53 patients in the observation group with addition of arolizumab on the basis of the control.The treatment efficacy and adverse reactions as well as the serum levels of vascular endothelial growth factor(VEGF),carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA),and alpha fetoprotein(AFP)before and after treatment were compared between the 2 groups.Results:After treatment,the total effective rate and the specific disease control rate(DCR)were signicantly higher in the observation group(45.28%and 71.70%,respectively)than in the control(25.93%and 38.89%,respectively)(χ^(2)=4.38,4.25,P=0.036,0.039).The serum levels of specific concentrations of CA19-9,VEGF,AFP and CEA were significantly lowere in the observation group[280.21±11.67)ng·L^(-1),(51.52±8.22)U·mL^(-1),(7.49±0.98)ng·mL^(-1),(21.37±3.19)ng·mL^(-1)]than in the control[(310.37±12.83)ng·L^(-1),(60.28±7.83)U·ml-1,(11.33±1.72)ng·mL^(-1),(28.51±4.28)ng·mL^(-1)](t=12.66,5.62,14.12,9.74,P<0.05).Conclusion:The combination of oxaliplatin and capecitabine with calerizumab in the treatment of advanced colorectal cancer patients has a good therapeutic efficacy and can be widely promoted in clinical practice.
作者
谢亚荣
余晓萍
王波
郭玮
王晓玲
XIE Ya-rong;YU Xiao-ping;WANG Bo;GUO Wei;WANG Xiao-ling(Department of Laboratory Tests,Yuncheng Central Hospital,Yuncheng 044000,China;Department of Oncology,Yuncheng Central Hospital,Yuncheng 044000,China;Department of Laboratory Tests,Shanxi Traditional Chinese Medical Hospital,Taiyuan 030012,China)
出处
《中国药物应用与监测》
CAS
2023年第5期316-319,共4页
Chinese Journal of Drug Application and Monitoring
基金
山西省应用基础研究计划项目(2021081)。
